Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for Taiwan.

"Authors' Disclosures K.Y. Chen reports personal fees from AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharma; and personal fees from Takeda outside the submitted work. H.H. Hung reports grants from Ministry of Science and Technology during the conduct of the study. C.J. Chen reports grants from Ministry of Science and Technology during the conduct of the study. I.S. Chang reports grants from Ministry of Health and Welfare, Taiwan during the conduct of the study. C.A. Hsiung reports grants from Department of Health Taiwan, Ministry of Health and Welfare Taiwan; and grants from Ministry of Science and Technology Taiwan during the conduct of the study. No disclosures were reported by the other authors."

"Part of the data analyzed in this study was provided by and analyzed on site in the Health and Welfare Data Science Center, MOHW, Taiwan. This study was supported by the MOHW (Project grants DOH95-TD-G-111–015 (to C.A. Hsiung), DOH101-TD-PB-111-TM015 (C.A. Hsiung), DOH102-TD-PB-111-TM024 (C.A. Hsiung), MOHW103-TDU-PB-211–144003 (to C.A. Hsiung), MOHW106-TDU-B-212–144013 (to I.S. Chang), MOHW107-TDU-B-212–114026 (to I.S. Chang)), NHRI (Project grants 95A1-BSAP01–002 (to C.A. Hsiung), NHRI-PH-110-GP-04 (to C.A. Hsiung), NHRI-PH-110-GP-01 (to C.A. Hsiung), and the Ministry of Science and Technology (MOST 103–2325-B-400–023 (to C.A. Hsiung), MOST 104–2325-B-400–012 (to C.A. Hsiung), MOST 105–2325-B-400–010 (to C.A. Hsiung), MOST 109–2740-B-400–002 (to C.A. Hsiung)."